F230
Pulmonary Arterial Hypertension
Not SpecifiedEvaluated
Key Facts
About Gyre Therapeutics
Gyre Therapeutics is a San Diego-based biotech focused on developing treatments for organ fibrosis, with a core mission to address the high unmet need in chronic liver and metabolic diseases. Its key achievement is the advancement of Hydronidone, which has secured Breakthrough Therapy designation in China for Hepatitis B-induced liver fibrosis and is now in a pivotal Phase 3 trial, while a Phase 2b study in MASH is planned for the U.S. The company's strategy is bifurcated: driving its lead candidate in major Western markets while leveraging its controlling interest in Beijing Continent to develop and commercialize a broader portfolio of fibrosis therapies across multiple indications in China and beyond.
View full company profileTherapeutic Areas
Other Pulmonary Arterial Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| Tadliq® (Tadalafil Oral Suspension) | CMP Pharma | Approved |
| Technosphere Platform (Partnered: Tyvaso DPI) | MannKind | Approved |
| JTV-161 | Akros Pharma | Phase1 |
| PROPHET | Occlutech | Pilot |
| Soft Mist Inhaler for PAH (with unnamed Pharma Partner) | Resyca | Not Disclosed |
| LTSE-2578 | Structure Therapeutics | Phase 1 |
| Tyvaso DPI® | MannKind Corp | Approved |